Actuate Therapeutics, Inc. Common stock
ACTUActuate Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing targeted therapies for the treatment of cancer and inflammatory diseases. The company is known for its research and development efforts aimed at addressing unmet medical needs through innovative drug candidates.
Company News
Actuate Therapeutics presented clinical data at ASCO 2026 showing that elraglusib combined with chemotherapy regimens (gemcitabine/Abraxane and FOLFIRINOX) demonstrated significant survival improvements in metastatic pancreatic cancer patients, particularly those with wild-type KRAS and TP53 genomics. The drug showed favorable tolerability across...
Actuate Therapeutics announced that CEO Dan Schmitt will present at the Citizens Life Sciences Conference on March 10, 2026. The company also plans to expand its clinical pipeline by advancing elraglusib tablet into a Phase 1/2 clinical program for refractory cancers, with the phase 1 portion planned to initiate in the second half of 2026.
Actuate Therapeutics successfully closed a $17.25 million public offering of 2,464,286 common stock shares at $7.00 per share, including the full exercise of an over-allotment option. The company plans to use the net proceeds of approximately $15.62 million for working capital and general corporate purposes.
Actuate Therapeutics' Phase 2 trial of elraglusib in combination with gemcitabine/nab-paclitaxel for first-line treatment of metastatic pancreatic ductal adenocarcinoma met its primary endpoint, demonstrating a clinically meaningful increase in median overall survival.
Actuate Therapeutics, a clinical-stage biopharmaceutical company, will present data on its investigational drug elraglusib for the treatment of advanced salivary gland carcinoma at the AACR Annual Meeting 2025. The data suggests elraglusib in combination with chemotherapy and immunotherapy may be a promising approach for this rare and difficult-t...
